DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
CGM Market Leade | Explore DexCom's dominant position in continuous glucose monitoring technology, driving innovation and expanding market reach in diabetes management |
Financial Resilience | Delve into DexCom's robust financial performance, with $4.15 billion in trailing twelve-month revenue and a strong gross margin of 59.43% |
Growth Catalysts | Uncover DexCom's strategic expansion into Type 2 diabetes market and international growth potential, positioning the company for sustained success |
Analyst Outlook | Average price target of $99, with analysts projecting potential outperformance and anticipating DexCom to exceed its conservative 2025 revenue guidance |
Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
---|---|---|---|---|
P/E Ratio | 58.6x | −4.7x | −0.5x | |
PEG Ratio | −4.40 | −0.16 | 0.00 | |
Price/Book | 13.8x | 3.6x | 2.6x | |
Price / LTM Sales | 7.6x | 2.5x | 3.0x | |
Upside (Analyst Target) | 25.0% | 99.3% | 52.4% | |
Fair Value Upside | Unlock | −21.7% | 8.7% | Unlock |